Journal: Materials Today Bio

Article Title: Scalable fabrication of freely shapable 3D hierarchical Cu-doped hydroxyapatite scaffolds via rapid gelation for enhanced bone repair

doi: 10.1016/j.mtbio.2024.101370

Figure Lengend Snippet: The in vivo evaluation of bone regeneration ability of the Cu-HAp porous scaffolds in rat skull defect model. Representative micro-CT images in sagittal and cross-section view in different groups after transplation for 6 weeks (a) and 12 weeks (b). (c) Statistical analysis of the newly formed bone mineral density (BMD) for 6 weeks and 12 weeks (n = 3,∗p < 0.05,∗∗p < 0.01,∗∗∗p < 0.001). (d) Quantitative statistical analyisis of the newly formed bone volume/total volume (BV/TV) for 6 weeks and 12 weeks.

Article Snippet: The porous scaffold underwent three-dimensional imaging using a micro-computed tomography (micro-CT) scanner (Skyscan 1272, Bruker, Germany) with a scanning resolution set at 5 μm, and X-ray energy and current at 50 kV and 500 μA, respectively.

Techniques: In Vivo, Micro-CT

Journal: Pain

Article Title: Antibody-induced pain-like behavior and bone erosion: links to subclinical inflammation, osteoclast activity, and acid-sensing ion channel 3–dependent sensitization

doi: 10.1097/j.pain.0000000000002543

Figure Lengend Snippet: Intravenous injection of B02/B09 mAbs alters bone homeostasis and induces bone erosion. Micro-CT analysis of the proximal tibia shows that B02/B09 (2 mg i.v.) significantly reduces (A) trabecular bone volume (BV/TV), (B) trabecular number (Tb.N), and (C) cortical thickness (Ct. Th) and increases (D) trabecular separations (Tb. Sp) compared with G09 control (G09) or saline (n = 6-19/group). (E) Human B02/B09 increases the total number of TRAP+ osteoclasts in vitro with a significant effect on the number of (F) small osteoclasts (4-9 nuclei), but not (G) big osteoclasts (4-9 nuclei) or (H) preosteoclasts (2-3 nuclei), compared with a control antibody (G09) (n = 5 samples/group). (I) In vivo scintigraphy at days 4 and 31 using the 99m Tc-HMDP radiotracer (n = 8-12 mice/group) and (J) in vivo imaging assessing cathepsin K activity at day 21 show that B02/B09 injection stimulates bone remodeling (n = 5/group), compared with saline-injected control. (K) In vivo scintigraphy at days 2 and 28 using the 99m Tc-NTP 15-5 radiotracer shows that B02/B09 does not induce cartilage remodeling (n = 12-14/group), compared with saline-injected control. Data presented as mean±SEM, * P < 0.05, ** P < 0.01, *** P < 0.001. Ctrl, control; OC, osteoclast; TcHMDP, technetium hydroxymethylene diphosphonate; TcNTP, technetium- N-[triethylammonium]-3-propyl- ane-N5; Unstim, unstimulated.

Article Snippet: Predeveloped probes (Applied Biosystems) for Acp5 (Mm00475698_m1), Ctsk (Mm00484039_m1), Tcirg1 (Mm00469406_m1), Asic3 (Mm00805460_m1), Asic1 (Mm01306001_g1), Il1β (Mm00434228_m1), Tnf (Mm00443258_m1), Il6 (Mm00446190_m1), Cxcl1 (Mm04207460_m1), Cxcl2 (Mm00436450_m1), Ptgs2 (Mm00478374_m1), Pla2g2a (Mm00448160_m1), Pla2g5 (Mm00448162_m1), Pla2g10 (Mm01344436_g1), Enpp2 (Mm00516572_m1), Lpar1 (Mm00439145_m1), Lpar2 (Mm00469562_m1), Lpar3 (Mm00469694_m1), Lpar4 (Mm01228532_m1), Lpar5 (Mm01190818_m1), and Lpar6 (Mm00163058) were used for mRNA analysis.

Techniques: Injection, Micro-CT, Control, Saline, In Vitro, In Vivo, In Vivo Imaging, Activity Assay

Journal: Pain

Article Title: Antibody-induced pain-like behavior and bone erosion: links to subclinical inflammation, osteoclast activity, and acid-sensing ion channel 3–dependent sensitization

doi: 10.1097/j.pain.0000000000002543

Figure Lengend Snippet: B02/B09-induced pain-like behavior is reversed by osteoclast inhibitors. (A) T06 (40 mg/kg) given daily by oral gavage for the whole duration of the study (1-14 days) prevents B02/B09-induced mechanical hypersensitivity, compared with the B02/B09 group treated with distilled water vehicle (n = 6-8/group). (B) Zoledronate (100ug/kg) administered i.p. on days 1, 4, 7, and 10 post-mAb injection prevents the development of B02/B09-induced pain-like behavior (n = 6/group). Statistical significance (2-way analysis of variance (ANOVA)) between B02/B09+vehicle and PBS+PBS/veh is marked by * and difference between B02/B09+vehicle and B02/B09+T06 or B02/B09+Zol is marked respectively with + or #. Data presented as mean±SEM; * P < 0.05; ** P < 0.01; ***,###, or +++ P < 0.001. Increased gene expression of (C) Acp5, (D) Ctsk , and (E) Tcirg1 in ankle joints of B02/B09-injected mice is prevented in zoledronate-treated mice (n = 6-12/group). Statistical significance (1-way ANOVA) between B02/B09-injected and PBS-injected control is marked by * and difference between B02/B09 and B02/B09+Zol is marked by #; * or # P < 0.05. T06, tanshinone IIA sulfonic sodium; Zol, zoledronate.

Article Snippet: Predeveloped probes (Applied Biosystems) for Acp5 (Mm00475698_m1), Ctsk (Mm00484039_m1), Tcirg1 (Mm00469406_m1), Asic3 (Mm00805460_m1), Asic1 (Mm01306001_g1), Il1β (Mm00434228_m1), Tnf (Mm00443258_m1), Il6 (Mm00446190_m1), Cxcl1 (Mm04207460_m1), Cxcl2 (Mm00436450_m1), Ptgs2 (Mm00478374_m1), Pla2g2a (Mm00448160_m1), Pla2g5 (Mm00448162_m1), Pla2g10 (Mm01344436_g1), Enpp2 (Mm00516572_m1), Lpar1 (Mm00439145_m1), Lpar2 (Mm00469562_m1), Lpar3 (Mm00469694_m1), Lpar4 (Mm01228532_m1), Lpar5 (Mm01190818_m1), and Lpar6 (Mm00163058) were used for mRNA analysis.

Techniques: Injection, Gene Expression, Control